Surging demand for GLP-1 receptor agonists has exposed structural limits in global sterile injectable packaging infrastructure. Leading pharmaceutical developers are constrained not by active pharmaceutical ingredient (API) synthesis, but by specialized fill-finish capacity.
Capital Outlays for Sterile Production
To relieve bottlenecks, drugmakers have committed over $12 billion toward expanding specialized auto-injector assembly lines and acquiring third-party Contract Development and Manufacturing Organizations (CDMOs). Supply parity is not anticipated prior to Q4 2025.